Candel Therapeutics, Inc.

US$8.75As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:CADLHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR 2.73%
Div yield —
ROE (81.84%)
Biotechnology
Beta (5Y) (0.29)
PE TTM —
TSR TTM 62.64%
Mkt cap US$669.5M
ROIC (32.81%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
20.29%
(88.45%)
Hold 9|2|7|7|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.16
0.18
0.19
0.18
3.83%
21.85%
26.33%
20.44%
Revenue$M
32.61
32.24
34.09
35.88
10.73%
6.27%
9.08%
12.67%
Peers (US$669.5M)
Cap (US$)
PE
666.5M
—
Capital
TTM
5Y
10Y
Leveragex
0.096
3.628
3.571
EBIT/Intx
0.282
0.055
0.054
Own earn%
7.67
144.55
140.45
Sh yield%
9.07
31.17
32.48
Owners
Insiders/Inst%
4.70
59.13
Short interest%
2.80
SBC / revenue%
1.35
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
3–10
$1 testx
0.0
Incr. ROIC%
7